[Research Progress of Anti-angiogenic Agents Combined with Immunotherapy 
in Patients with Advanced Non-small Cell Lung Cancer].

ABSTRACT: Lung cancer has the highest incidence rate and mortality in China, even in the world, and non-small cell lung cancer (NSCLC) accounts for about 85%. The growth and metastasis of tumor depend on the generation of blood vessels, and anti-angiogenic therapy is playing an increasingly important role, however, no significant improvement was observed in the underwent anti-angiogenic agents used for patients alone. In recent years, the application of immune checkpoint inhibitor (ICI) has significantly improved the prognosis of some lung cancer patients, however, the objective response rate of patients receiving ICI alone is low. While anti-angiogenic agents and ICI both regulate the tumor immune microenvironment and have a potential synergistic mechanism, showing a bright prospect in the combined

SUBMITTER: Wang J 

PROVIDER: S-EPMC8143969 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature